Literature DB >> 22851646

Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.

Marsha D Wallace1, Adam D Pfefferle, Lishuang Shen, Adrian J McNairn, Ethan G Cerami, Barbara L Fallon, Vera D Rinaldi, Teresa L Southard, Charles M Perou, John C Schimenti.   

Abstract

Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity. Relevant mouse models are powerful for untangling this problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit high levels of genomic instability leading to mammary tumors that have tumor gene expression profiles closely resembling mature human mammary luminal cell signatures. We genomically characterized mammary adenocarcinomas from these mice to identify cancer-causing genomic events that overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in nearly all cases. These overlap with human CNAs including NF1, which is deleted or mutated in 27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS hyperactivation and increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 loss can drive breast cancer. This should be informative for treatment of the significant fraction of patients whose tumors bear NF1 mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851646      PMCID: PMC3454871          DOI: 10.1534/genetics.112.142802

Source DB:  PubMed          Journal:  Genetics        ISSN: 0016-6731            Impact factor:   4.562


  51 in total

1.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

2.  Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization.

Authors:  Jiyun Lee; Jianzhou Wang; Michael Torbenson; You Lu; Qiong Z Liu; Shibo Li
Journal:  Cancer Genet Cytogenet       Date:  2010-01-15

3.  Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Zhengyan Kan; Bijay S Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M Stern; Peng Yue; Peter M Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P Tomsho; Brock A Peters; Kanan Pujara; Shaun Cordes; David P Davis; Victoria E H Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S Kaminker; David A Eberhard; Paul Waring; Stephan C Schuster; Zora Modrusan; Zemin Zhang; David Stokoe; Frederic J de Sauvage; Malek Faham; Somasekar Seshagiri
Journal:  Nature       Date:  2010-07-28       Impact factor: 49.962

4.  Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1.

Authors:  Yoshimi Arima; Hidemi Hayashi; Kanako Kamata; Takaaki M Goto; Mikako Sasaki; Akira Kuramochi; Hideyuki Saya
Journal:  Exp Dermatol       Date:  2010-08       Impact factor: 3.960

5.  Incremental genetic perturbations to MCM2-7 expression and subcellular distribution reveal exquisite sensitivity of mice to DNA replication stress.

Authors:  Chen-Hua Chuang; Marsha D Wallace; Christian Abratte; Teresa Southard; John C Schimenti
Journal:  PLoS Genet       Date:  2010-09-09       Impact factor: 5.917

6.  KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death.

Authors:  Arasambattu K Munirajan; Kiyohiro Ando; Akira Mukai; Masato Takahashi; Yusuke Suenaga; Miki Ohira; Tadayuki Koda; Toru Hirota; Toshinori Ozaki; Akira Nakagawara
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

7.  Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.

Authors:  Frederick Kweh; Min Zheng; Elena Kurenova; Margaret Wallace; Vita Golubovskaya; William G Cance
Journal:  Mol Carcinog       Date:  2009-11       Impact factor: 4.784

8.  Breast cancer associated with type 1 neurofibromatosis.

Authors:  Nikolaos S Salemis; Georgios Nakos; Dimitrios Sambaziotis; Stavros Gourgiotis
Journal:  Breast Cancer       Date:  2009-05-23       Impact factor: 4.239

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Aneuploidy and improved growth are coincident but not causal in a yeast cancer model.

Authors:  Xin Chenglin Li; John C Schimenti; Bik K Tye
Journal:  PLoS Biol       Date:  2009-07-28       Impact factor: 8.029

View more
  33 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

3.  Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.

Authors:  Leander Blaas; Fabio Pucci; Hendrik A Messal; Agneta B Andersson; E Josue Ruiz; Marco Gerling; Iyadh Douagi; Bradley Spencer-Dene; Alexandra Musch; Richard Mitter; Leena Bhaw; Richard Stone; Dorothee Bornhorst; Abdul K Sesay; Jos Jonkers; Gordon Stamp; Ilaria Malanchi; Rune Toftgård; Axel Behrens
Journal:  Nat Cell Biol       Date:  2016-10-31       Impact factor: 28.824

4.  In utero exposure of rats to high-fat diets perturbs gene expression profiles and cancer susceptibility of prepubertal mammary glands.

Authors:  Vinothini Govindarajah; Yuet-Kin Leung; Jun Ying; Robin Gear; Robert L Bornschein; Mario Medvedovic; Shuk-Mei Ho
Journal:  J Nutr Biochem       Date:  2015-11-26       Impact factor: 6.048

Review 5.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

Review 6.  Dormant origins as a built-in safeguard in eukaryotic DNA replication against genome instability and disease development.

Authors:  Naoko Shima; Kayla D Pederson
Journal:  DNA Repair (Amst)       Date:  2017-06-09

7.  Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations.

Authors:  Elias A Chandran; Ian Kennedy
Journal:  J Immunother Precis Oncol       Date:  2020-05-18

Review 8.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

9.  The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.

Authors:  Nithya Kartha; Lishuang Shen; Carolyn Maskin; Marsha Wallace; John C Schimenti
Journal:  Genetics       Date:  2016-06-08       Impact factor: 4.562

10.  KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Authors:  J Stebbing; H Zhang; Y Xu; L C Lit; A R Green; A Grothey; Y Lombardo; M Periyasamy; K Blighe; W Zhang; J A Shaw; I O Ellis; H J Lenz; G Giamas
Journal:  Oncogene       Date:  2014-06-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.